# Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

> **NCT05050474** · PHASE1 · COMPLETED · sponsor: **Livzon Pharmaceutical Group Inc.** · enrollment: 43 (actual)

## Conditions studied

- COVID19

## Interventions

- **BIOLOGICAL:** Recombinant SARS-CoV-2 Fusion Protein Vaccine

## Key facts

- **NCT ID:** NCT05050474
- **Lead sponsor:** Livzon Pharmaceutical Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-07
- **Primary completion:** 2022-02-18
- **Final completion:** 2022-02-18
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-04-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05050474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05050474, "Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05050474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*